Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines

作者：Paaladinesh Thavendiranathan, Christian Houbois, Thomas H. Marwick, Tiffanie Kei, Sudipta Saha, Kyle Runeckles, Flora Huang, Tamar Shalmon, Kevin E. Thorpe, Rossanna C. Pezo, Anca Prica, Dawn Maze, Husam Abdel‐Qadir, Kim A. Connelly, Joyce Y.T. Chan, Filio Billia, Coleen Power, Kate Hanneman, Bernd J. Wintersperger, Christine Brezden‐Masley, Eitan Amir · 发表于：European Heart Journal - Cardiovascular Pharmacotherapy · 年份：2023 · DOI：10.1093/ehjcvp/pvad031 · 被引用次数：114 · 研究领域：Chemotherapy-induced cardiotoxicity and mitigation、Cancer, Lipids, and Metabolism、Lung Cancer Research Studies

BACKGROUND AND AIMS: Anthracyclines can cause cancer therapy-related cardiac dysfunction (CTRCD). We aimed to assess whether statins prevent decline in left ventricular ejection fraction (LVEF) in anthracycline-treated patients at increased risk for CTRCD. METHODS: In this multicenter double-blinded, placebo-controlled trial, patients with cancer at increased risk of anthracycline-related CTRCD (per ASCO guidelines) were randomly assigned to atorvastatin 40 mg or placebo once-daily. Cardiovascular magnetic resonance (CMR) imaging was performed before and within 4 weeks after anthracyclines. Blood biomarkers were measured at every cycle. The primary outcome was post-anthracycline LVEF, adjusted for baseline. CTRCD was defined as a fall in LVEF by >10% to <53%. Secondary endpoints included left ventricular (LV) volumes, CTRCD, CMR tissue characterization, high sensitivity troponin I (hsTnI), and B-type natriuretic peptide (BNP). RESULTS: We randomized 112 patients (56.9 ± 13.6 years, 87 female, and 73 with breast cancer): 54 to atorvastatin and 58 to placebo. Post-anthracycline CMR was performed 22 (13-27) days from last anthracycline dose. Post-anthracycline LVEF did not differ between the atorvastatin and placebo groups (57.3 ± 5.8% and 55.9 ± 7.4%, respectively) when adjusted for baseline LVEF (P = 0.34). There were no significant between-group differences in post-anthracycline LV end-diastolic (P = 0.20) or end-systolic volume (P = 0.12), CMR myocardial edema and/or fibrosi...